Clinical Trial Update: A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM [Phase 1]

View source ↗

Summary

Phase 1 study evaluating PVX-410 cancer vaccine with citarinostat, with or without lenalidomide, in patients with smoldering multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• PVX-410
• citarinostat (citarinostat)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Smoldering Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING